Brooks Laboratories

Brooks Laboratories Inventory

The Inventory of Brooks Laboratories (BROOKS.NS) as of Nov 6, 2026 is 110.22 M INR. In the previous year, Inventory was 92.05 M INR — a change of 19.74% (higher).

Inventory

110.22 MINR

YoY

19.74%

Last updated:

Inventory of Brooks Laboratories is 2026 110.22 M INR. Inventory of Brooks Laboratories was 2025 92.05 M INR. It decreases by 19.74% higher compared to the previous year.

The Brooks Laboratories Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
100.53 M INR
Jan 1, 2020
137.75 M INR
Jan 1, 2021
236.03 M INR
Jan 1, 2022
275.22 M INR
Jan 1, 2023
113.03 M INR
Jan 1, 2024
96.11 M INR
Jan 1, 2025
92.05 M INR
Jan 1, 2026
110.22 M INR
The Brooks Laboratories Inventory history
YEARInventoryYoY
110.22 MINR+19.74%
92.05 MINR-4.22%
96.11 MINR-14.97%
113.03 MINR-58.93%
275.22 MINR+16.61%
236.03 MINR+71.35%
137.75 MINR+37.02%
100.53 MINR-11.88%
114.09 MINR+48.19%
76.99 MINR+15.10%
66.89 MINR-11.21%
75.34 MINR+24.97%
60.29 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brooks Laboratories Stock analysis

What does Brooks Laboratories do? Brooks Laboratories Ltd. manufactures pharmaceutical products including Carbapenem category drugs such as Imipenem 250mg + Cilastatin 250mg, Meropenem 125mg, and Doripenem 500mg. The company produces Penicillins in injections, tablets, and dry syrup forms, along with General category products like liquid injections, dry powder injections, and eye/ear drops. Brooks Laboratories markets its pharmaceuticals nationally and internationally to regulated markets through its manufacturing plants in Baddi, Himachal Pradesh. The firm generates revenue by selling these dosage forms to healthcare providers and distributors in regulated pharmaceutical markets. The company's product portfolio includes specific formulations like Iron sucrose 100mg/5ml liquid injections under the General category. Brooks Laboratories targets regulated markets globally for its Carbapenem, Penicillin, and General category products. Its manufacturing operations at Baddi enable nationwide and international distribution of pharmaceuticals. Revenue is derived from the sale of these branded and generic pharmaceutical products to hospitals, pharmacies, and international buyers in compliant markets. Brooks Laboratories focuses on producing injectable and oral dosage forms including tablets, dry syrup, and eye/ear drops. The company's Carbapenem category features Meropenem 1000mg+Tazobactam 500mg and Doripenem 1000mg. Penicillins are available as injections, tablets, and dry syrup. The firm's revenue model relies on direct sales of these pharmaceutical products to healthcare institutions and distributors in regulated markets, ensuring compliance with international pharmaceutical standards. Brooks Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brooks Laboratories stock

Inventory of Brooks Laboratories is 110.22 M INR in 2026.

Inventory of Brooks Laboratories changed from 92.05 M INR to 110.22 M INR, representing a 19.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Brooks Laboratories since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Brooks Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Brooks Laboratories

All Key Metrics — Brooks Laboratories